DDInter150 DDInter1324
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-20 monoclonal antibody used in the treatment of rheumatoid arthritis and B-cell non-Hodgkin's lymphoma, ofatumumab has a higher affinity towards CD20. Ofatumumab is available for intravenous administration and is marketed as Arzerra. In Phase III clinical trials consisting of subjects with relapsing forms of multiple sclerosis (RMS), subcutaneous administration of ofatumumab reduced the number of relapses and delayed disease progression. In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of RMS in adults. The FDA subsequently approved ofatumumab for the treatment of RMS on August 20, 2020. The potential therapeutic use of ofatumumab in various lymphomas and rheumatoid arthritis has also been investigated.
Azathioprine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine {u} (Compound) downregulates {v} (Gene) SUZ12
SUZ12 {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Ofatumumab
Azathioprine {u} (Compound) upregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Ofatumumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Deferiprone
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Ofatumumab
Azathioprine {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Radium Ra 223 dichloride
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Nucleoside Analog {u} (Pharmacologic Class) includes {v} (Compound) Valganciclovir
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofatumumab
Azathioprine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Azathioprine (Compound) downregulates SUZ12 (Gene) and SUZ12 (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Azathioprine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Ofatumumab
Azathioprine (Compound) upregulates GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Azathioprine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Azathioprine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Ofatumumab
Azathioprine (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Deferiprone (Compound) and Deferiprone may lead to a major life threatening interaction when taken with Ofatumumab
Azathioprine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Radium Ra 223 dichloride (Compound) and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Azathioprine (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Valganciclovir (Compound) and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab